{"a":[{"_":"FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute","$":{"href":"/biotech/fda-adcomm-shoots-down-capricors-duchenne-cell-therapy-after-meeting-marked-statistical","hreflang":"en"}}]}
AdComrejectedNegative
AI Analysis
Summary
An FDA advisory committee voted against Capricor's cell therapy for Duchenne muscular dystrophy following a meeting marked by statistical disputes. The negative recommendation represents a significant regulatory setback for the company's therapeutic candidate.
Outcome Details
FDA advisory committee voted against the cell therapy
Importance:8/10
Sentiment:
-0.90
FDAadvisory committeecell therapyDuchenne muscular dystrophyregulatory rejection
Related Companies
Read the original article
Published by FierceBiotech on July 29, 2026 5:51 PM